GSK Secures Updated FDA Approval Letter for TWINRIX Combination Hepatitis Vaccine in May 2026

A May 2026 approval letter from FDA for GlaxoSmithKline Biologicals' TWINRIX signals an active regulatory file for one of the agency's longest-standing combination biologics, and for QA directors managing hepatitis vaccine portfolios, that means labeling, lot release, and post-approval change documentation warrant a fresh review cycle.

TWINRIX (Hepatitis A & Hepatitis B [Recombinant] Vaccine, STN: BL 103850) is indicated for active immunization against disease caused by hepatitis A virus and infection by all known subtypes of hepatitis B virus. The May 14, 2026 approval letter is the most recent in a documented sequence that includes letters dated April 28, 2023, and December 18, 2018, reflecting a pattern of periodic regulatory correspondence consistent with post-approval supplement activity under 21 CFR Part 601.

For biologics QA teams, recurring approval letters on a mature product typically accompany labeling revisions, manufacturing changes, or post-market commitments, each of which triggers downstream obligations across batch record review, comparability protocols, and updated package insert distribution. The three-letter sequence visible in the FDA product page suggests GlaxoSmithKline has maintained an active supplement cadence roughly every three to four years, a timeline that aligns with standard post-approval change management expectations under ICH Q10.

Regulatory affairs leads tracking combination vaccine approvals should note that the public-facing product page now archives supporting documents older than three years separately, which may affect how teams reconstruct the regulatory history for internal audits or agency inspections. Ensuring that the current package insert version is reconciled against the May 2026 letter is a near-term action item for any site distributing or quality-releasing TWINRIX lots.

The next compliance checkpoint for GlaxoSmithKline will likely center on whether the May 2026 letter reflects a labeling supplement, a manufacturing post-approval change, or a combination, details that will become visible once the updated package insert is published to the FDA product page.

Source: FDA Vaccines, Blood & Biologics product page (What's New: Vaccines, Blood & Biologics RSS Feed), May 15, 2026.